Literature DB >> 3293641

Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine.

A Rozkovec1, J R Stradling, G Shepherd, J MacDermot, C M Oakley, C T Dollery.   

Abstract

Eighteen patients with moderate to severe pulmonary hypertension were studied, nine with intracardiac shunts and nine without. The effects of an incremental infusion of epoprostenol (prostacyclin) (0.5-8 ng/kg per minute) or sublingual nifedipine (20-30 mg) were compared with the response to three months' treatment with oral nifedipine. Both epoprostenol and sublingual nifedipine caused a fall in pulmonary vascular resistance and pressure and a rise in cardiac output. Patients with intracardiac shunts had higher systemic blood flows than those without shunts. Exercise in the shunt group was accompanied by systemic desaturation and hyperventilation. Analysis of individual results showed that the size of the response was inversely related to the severity of the pulmonary vascular disease. A good long term response to nifedipine seemed to be as readily predicted by the resting control values for haemodynamic variables as by values after short term treatment. A favourable response was likely if the pretreatment mean pulmonary artery pressure was less than 50 mm Hg, the ratio of total pulmonary to systemic resistance was less than 0.7, or the ratio of mean pulmonary artery pressure to systemic artery pressure was less than 0.6. Short term vasodilator protocols may do harm. If such studies are carried out, an adequate dose range must be tried before the long term efficacy of an individual drug can be forecast.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293641      PMCID: PMC1276879          DOI: 10.1136/hrt.59.6.696

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  28 in total

1.  Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response.

Authors:  S Rich; J Martinez; W Lam; P S Levy; K M Rosen
Journal:  Am Heart J       Date:  1983-01       Impact factor: 4.749

2.  The accuracy of the Hewlett-Packard 47201A ear oximeter below 50% saturation.

Authors:  J R Stradling
Journal:  Bull Eur Physiopathol Respir       Date:  1982 Sep-Oct

3.  Circulatory effects of coffee in relation to the pharmacokinetics of caffeine.

Authors:  P Smits; T Thien; A van't Laar
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

4.  Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.

Authors:  G Simonneau; P Escourrou; P Duroux; A Lockhart
Journal:  N Engl J Med       Date:  1981-06-25       Impact factor: 91.245

5.  Effect of flow and pressure on pulmonary vessels. A semiquantitative study based on lung biopsies.

Authors:  C A Wagenvoort; J Nauta; P J van der Schaar; H W Weeda; N Wagenvoort
Journal:  Circulation       Date:  1967-06       Impact factor: 29.690

6.  The effect of isoproterenol on the development and recovery of hypoxic pulmonary hypertension. A structural and hemodynamic study.

Authors:  R Fried; L M Reid
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

7.  The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause.

Authors:  E Lupi-Herrera; J Sandoval; M Seoane; D Bialostozky
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

8.  Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. A controlled double-blind study.

Authors:  T P Kennedy; J R Michael; C K Huang; C H Kallman; K Zahka; W Schlott; W Summer
Journal:  Am Rev Respir Dis       Date:  1984-04

9.  Oral hydralazine therapy for primary pulmonary hypertension.

Authors:  L J Rubin; R H Peter
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

10.  Effects of nifedipine on contractile responses to potassium, histamine, and 5-hydroxytryptamine in isolated human pulmonary vessels.

Authors:  E O Mikkelsen; A M Sakr; L T Jespersen
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

View more
  5 in total

1.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

2.  Clinical correlates of angiographically diagnosed idiopathic pulmonary hypertension.

Authors:  H H Gray; J M Morgan; I H Kerr; G A Miller
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

3.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.

Authors:  T W Higenbottam; D Spiegelhalter; J P Scott; V Fuster; A T Dinh-Xuan; N Caine; J Wallwork
Journal:  Br Heart J       Date:  1993-10

4.  Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery.

Authors:  J Kermode; W Butt; F Shann
Journal:  Br Heart J       Date:  1991-08

Review 5.  Calcium channel blockers for pulmonary arterial hypertension.

Authors:  Zhiyu Fan; Yuanjing Chen; Hanmin Liu
Journal:  Cochrane Database Syst Rev       Date:  2015-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.